Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys

Psychopharmacology

Volumn 222, Issue 3, 2012, Pages 425-438

  Schulze, David R ^a   Carroll, F Ivy ^b   McMahon, Lance R ^a  

^a University of Texas Health Science Center   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Cannabis; Delta 9 tetrahydrocannabinol; Dependence; Dopamine; Drug discrimination; Marijuana; Monkey; Rimonabant; Withdrawal

Indexed keywords

3BETA (4 CHLOROPHENYL) 2BETA TROPANECARBOXYLIC ACID PHENYL ESTER; 3BETA (4 CHLOROPHENYL)TROPANE 2BETA (3 PHENYLISOXAZOL 5 YL); 3BETA (4 CHLOROPHENYL)TROPANE 2BETA CARBOXYLIC ACID PHENYL ESTER; AMFEBUTAMONE; AMPHETAMINE; CANNABINOID RECEPTOR; COCAINE; DESIPRAMINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; HALOPERIDOL; IMIPRAMINE; RIMONABANT; RTI 177; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG DISCRIMINATION; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RELEASE; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RHESUS MONKEY;

AMPHETAMINE; ANIMALS; COCAINE; DISCRIMINATION LEARNING; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; IMIPRAMINE; MACACA MULATTA; MALE; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; TETRAHYDROCANNABINOL; TROPANES;

EID: 84864461541     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2661-9     Document Type: Article

References (42)

1. Anderson JJ, Kask AM, Chase TN (1996) Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. Eur J Pharmacol 295:163-168
2. Balster RL, Prescott WR (1992) δ9-tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 16:55-62
3. Cheer JF, Kendall DA, Mason R, Marsden CA (2003) Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum. Neuropharmacology 44:633-641
4. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24:4393-4400
5. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990) δ9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156-162
6. Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of delta 9-tetrahydrocannabinolinduced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594
7. D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E (2008) Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology 198:587-603
8. Diana M, Melis M, Muntoni AL, Gessa GL (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95:10269-10273
9. Evans MA, Martz R, Rodda BE, Lemberger L, Forney RB (1976) Effects of marihuana-dextroamphetamine combination. Clin Pharmacol Ther 20:350-358
10. Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD (1987) Marijuana and cocaine interactions in humans: Cardiovascular consequences. Pharmacol Biochem Behav 28:459-464
11. Foltin RW, Fischman MW, Pippen PA, Kelly TH (1993) Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Drug Alcohol Depend 32:93-106
12. Gauvin DV, Young AM (1989) Evidence for perceptual masking of the discriminative morphine stimulus. Psychopharmacology 98:212-221
13. Gessa GL, Melis M, Muntoni AL, Diana M (1998) Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341:39-44
14. Giuffrida A, Parsons LH, Kerr TM, Rodríguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358-363
15. Gorriti MA, Rodríguez de Fonseca F, Navarro M, Palomo T (1999) Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 365:133-142
16. Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW (2001) Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 155:171-179
17. Hattendorf C, Hattendorf M, Coper H, Fernandes M (1977) Interaction between δ9-tetrahydrocannabinol and d-amphetamine. Psychopharmacology 54:177-182
18. Holtzman D, Lovell RA, Jaffe JH, Freedman DX (1969) 1-δ9- tetrahydrocannabinol: Neurochemical and behavioral effects in the mouse. Science 163:1464-1467
19. Järbe TUC (1984) Discriminative stimulus properties of cocaine. Effects of apomorphine, haloperidol, procaine and other drugs. Neuropharmacology 23:899-907
20. Kamien JB, Woolverton WL (1989) A pharmacological analysis of the discriminative stimulus properties of d-amphetamine in rhesus monkeys. J Pharmacol Exp Ther 248:938-946
21. Kimmel HL, Negus SS, Wilcox KM, Ewing SB, Stehouwer J, Goodman MM, Votaw JR, Mello NK, Carroll FI, Howell LL (2008) Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav 90:453-462
22. Kleven MS, Anthony EW, Woolverton WL (1990) Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 254:312-317
23. Koe BK (1976) Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J Pharmacol Exp Ther 199:649-661
24. Kotian P, Abraham P, Lewin AH, Mascarella SW, Boja JW, Kuhar MJ, Carroll FI (1995) Synthesis and ligand binding study of 3 beta-(4'-substituted phenyl)-2 beta-(heterocyclic)tropanes. J Med Chem 38:3451-3453
25. Lew EO, Richardson JS (1981) Neurochemical and behavioural correlates of the interaction between amphetamine and δ9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 8:93-101
26. Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K (2008) Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54:815-823
27. Masserano JM, Karoum F, Wyatt RJ (1999) SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine. Behav Pharmacol 10:429-432
28. McMahon LR (2006) Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218
29. McMahon LR (2010) Chronic δ9-tetrahydrocannabinol treatment in rhesus monkeys: Differential tolerance and cross-tolerance among cannabinoids. Br J Pharmacol 162:1060-1073
30. Moranta D, Esteban S, García-Sevilla JA (2009) Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain. Naunyn Schmiedebergs Arch Pharmacol 379:61-72
31. National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. National Academies Press, Washington
32. Pistis M, Porcu G, Melis M, Diana M, Gessa GL (2001) Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 14:96-102
33. Poddar MK, Dewey WL (1980) Effects of cannabinoids on catecholamine uptake and release in hypothalamic and striatal synaptosomes. J Pharmacol Exp Ther 214:63-67
34. Solinas M, Justinova Z, Goldberg SR, Tanda G (2006) Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 98:408-419
35. Solinas M, Tanda G,Wertheim CE, Goldberg SR (2010) Dopaminergic augmentation of δ9-tetrahydrocannabinol (THC) discrimination: Possible involvement of D2-induced formation of anandamide. Psychopharmacology 209:191-202
36. Stewart JL, McMahon LR (2010) Rimonabant-induced δ9- tetrahydrocannabinol withdrawal in rhesus monkeys: Discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 334:347-356
37. Tallarida RJ (2000) Drug synergism and dose-effect data analysis. Chapman and Hall/CRC, Boca Raton, pp 44-50
38. Tanda G, Pontieri FE, Di Chiara G (1997) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276:2048-2050
39. Tanda G, Loddo P, Di Chiara G (1999) Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol 376:23-26
40. Wegel RL, Lane CE (1924) The auditory masking of one pure tone by another and its probable relation to the dynamics of the inner ear. Physiol Rev 23:266-285
41. Wu X, French ED (2000) Effects of chronic δ9-tetrahydrocannabinol on rat midbrain dopamine neurons: An electrophysiological assessment. Neuropharmacology 39:391-398
42. Zalcman S, Liskow B, Cadoret R, Goodwin D (1973) Marijuana and amphetamine: The question of interaction. Am J Psychiatry 130:707-708